Saniabadi Abbi R, Hanai Hiroyuki, Fukunaga Ken, Sawada Koji, Shima Chikako, Bjarnason Ingvar, Lofberg Robert
JIMRO Laboratories, 351-1 Nishiyokote Machi, Takasaki, Japan.
Transfus Apher Sci. 2007 Oct;37(2):191-200. doi: 10.1016/j.transci.2007.08.003. Epub 2007 Oct 31.
The inference that granulocytes and monocytes/macrophages (GM) are part of the immunopathogenesis of inflammatory bowel disease (IBD) and hence should be targets of therapy stems from observations of elevated, and activated GM in patients with IBD. The Adacolumn can selectively deplete GM by adsorption (GMA) and in patients with IBD, GMA has been associated with significant clinical efficacy together with sustained suppression of inflammatory cytokine profiles. Additionally, GMA depleted proinflammatory CD14(+)CD16(+) monocytes and was followed by an increase in CD4(+) T lymphocytes including the regulatory CD4(+)CD25(high+)Foxp3 phenotype. Hence, GMA could be a non-pharmacologic therapy for IBD with potential to spare steroids and other unsafe pharmacologic preparations.
粒细胞和单核细胞/巨噬细胞（GM）是炎症性肠病（IBD）免疫发病机制的一部分，因此应成为治疗靶点，这一推断源于对IBD患者中GM升高且活化的观察。吸附柱（Adacolumn）可通过吸附作用选择性清除GM（GMA），在IBD患者中，GMA已显示出显著的临床疗效，并能持续抑制炎症细胞因子谱。此外，GMA清除了促炎的CD14(+)CD16(+)单核细胞，随后CD4(+) T淋巴细胞增加，包括调节性CD4(+)CD25(high+)Foxp3表型。因此，GMA可能是一种治疗IBD的非药物疗法，有潜力避免使用类固醇和其他不安全的药物制剂。
